Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Post by JLGeminion Dec 23, 2010 10:00am
553 Views
Post# 17887644

Increased Trading - Good Sign

Increased Trading - Good Sign

My fear as we entered the last half of December was the trading volumes of Oncolytics on the NASDAQ and TXM would drop through the floor.  Distractions of the Holiday Season and year end close offs would reduce the buying pressure.  Low trading volumes would allow the investment club to sell down the ladder and spike the stock price to produce a depressed year end close.  With 5 days of trading remaining on the TXM, the interest in Oncolytics remains high.  The combined trading volume yesterday was 320,000 shares.  I can not believe the fools who are selling their shares with the short term 6 month outlook saying the stock price will double again.  The smart money is buying.

 

Back on June 17, I posted Reduced Trading – Good Sign.  The daily trading volumes were reducing by 50% to a combined 50,000 shares.  Sellers were starting to not being fooled to give away their shares at unrealistic price of $3.00.  The investment club had the advantage of limited outside buying pressure and being influential on this Discussion Board.  Today is a different story.  Outside interest in buying Oncolytics has increased 6 fold and January will see the trading volume increase to higher levels.  The period to deceive the market is over.  The market capitalization is moving to reflect the value of Reolysin and $500 million is only the beginning.  Expect $1 billion by the time the snow melts in Winnipeg.

 

The last five trading days will be the last chance to buy Oncolytics before the market rally commences in earnest in January.  Sellers will be better off spending time with family and friends than dumping their shares in the slow period before New Year's.

Bullboard Posts